Aurinia Pharmaceuticals Inc.
NASDAQ:AUPHBiotechnology
+$0.13 today
- Market cap
- $2.03B
- Beta
- 1.43
- P/E (TTM)
- 7.2
- EPS (TTM)
- $2.25
Volume 0.76M
Average 1.21M
AUPH Total Liabilities
Everything the company owes to creditors and other parties.
Aurinia Pharmaceuticals Inc.NASDAQ: AUPH
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 6.1% from a year ago
Total liabilities stood at $177.4M at the end of Q2 FY2026, up 6.1% from a year earlier and up 13.4% from the prior quarter. Over 3 fiscal years it compounded at +37.5% a year.
Context
- Total liabilities amounted to 22.4% of total assets at the end of Q2 FY2026, down 10.9 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +6.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 170.26M USD
- Year-over-year change
- -1.7%
- 4-year CAGR
- +27.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 170.26M | -1.7% |
| FY2024 | 2024-12-31 | 173.17M | +1.8% |
| FY2023 | 2023-12-31 | 170.11M | +160.0% |
| FY2022 | 2022-12-31 | 65.43M | +1.8% |
| FY2021 | 2021-12-31 | 64.28M | — |
Total Liabilities vs competitors
How AUPH compares with its peers on the latest reported figures
- AUPH's Jun 2026 total liabilities of $177.4M is the 2nd highest of the 10 companies compared; the peer median is $55.07M.
- Its year-over-year change of +6.1% is the 4th highest of 9, against a peer median of +0.4%.
- Total liabilities amounts to 22.4% of total assets for AUPH, versus a peer median of 23.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $358.52M | -13.8% | +48.1% | 96.7% | |
| Jun 2026 | $177.4M | +6.1% | +37.5% | 22.4% | |
| Mar 2026 | $146.35M | +48.3% | +145.8% | 36.6% | |
| Jun 2026 | $125.23M | +13.6% | +33.7% | 23.5% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $108.46M | -13.6% | -28.6% | 19.3% |
| Mar 2026 | $55.07M | +1.9% | +0.2% | 27.7% | |
| Mar 2026 | $46.21M | -1.1% | +117.0% | 31.5% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $33.11M | +108.5% | — | 11.4% |
EVMNEvommune, Inc. | Mar 2026 | $17.9M | -91.6% | — | 5.6% |
| Jun 2026 | $15.58M | — | — | 12.1% | |
| Peer median (excluding AUPH) | $55.07M | +0.4% | +40.9% | 23.5% | |
Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 231.9M | 94.17M | 48.88M | 83.43M | 80.21M |
| Short-term Investments | 234.18M | 295.22M | 301.61M | 275.04M | 317.78M |
| Net Receivables | 15.41M | 13.48M | 24.09M | 36.54M | 41.45M |
| Inventory | 19.33M | 24.75M | 39.71M | 39.23M | 45.69M |
| Other Current Assets | 796K | 1.33M | 1.03M | 1.13M | 1.08M |
| Total Current Assets | 513.32M | 442.54M | 424.8M | 446.6M | 491.97M |
| Property, Plant & Equipment (Net) | 9.8M | 8.56M | 116.57M | 98.87M | 79.57M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 8.4M | 6.43M | 4.98M | 4.36M | 3.76M |
| Long-term Investments | 0 | 0 | 201K | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 176.19M |
| Other Non-current Assets | 11.84M | 13.34M | 1.52M | 823K | 93K |
| Total Non-current Assets | 30.04M | 28.32M | 123.26M | 104.05M | 259.62M |
| Total Assets | 543.37M | 470.86M | 548.06M | 550.65M | 751.59M |
| Account Payables | 3.88M | 3.09M | 4.33M | 5.19M | 3.31M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 814K | 625K | 667K | 0 | 0 |
| Deferred Revenue | 190K | 3.15M | 4.81M | 11M | 3.72M |
| Other Current Liabilities | 4.45M | 2.03M | 1.59M | 1.53M | 2.48M |
| Total Current Liabilities | 40.65M | 46.11M | 77.19M | 97.76M | 93.72M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 12.65M |
| Other Non-current Liabilities | 15.95M | 12.17M | 10.91M | 11.11M | 6.66M |
| Total Non-current Liabilities | 23.63M | 19.32M | 92.92M | 75.4M | 76.53M |
| Total Liabilities | 64.28M | 65.43M | 170.11M | 173.17M | 170.26M |
| Common Stock | 1.18B | 1.19B | 1.2B | 1.19B | 1.12B |
| Retained Earnings | (756.12M) | (864.3M) | (942.32M) | (936.57M) | (649.37M) |
| Accumulated OCI | (852K) | (1.06M) | (730K) | (647K) | (599K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 479.09M | 405.44M | 377.95M | 377.48M | 581.33M |
| Total Debt | 8.74M | 8.09M | 97.61M | 79.37M | 74.81M |
| Net Debt | (223.16M) | (86.08M) | 48.73M | (4.06M) | (5.4M) |
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
Intrinsic Alpha fair value
Locked
Current Price
$15.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.